Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901016 | 0.82 | SLC6A4 (0.49) | MAOAGABRA1GABRB2PNMTSLC6A4 | |
| SCHEMBL25144725 | 0.82 | MAOA (0.36) | MAOAMAOBGABRA1GABRB2PNMT | |
| SCHEMBL5018830 | 0.78 | SLC6A4 (0.46) | MAOAGABRA1GABRB2PNMTPOLB | |
| SCHEMBL12417828 | 0.77 | MAOA (0.50) | MAOAMAOBARNPC1POLB | |
| SCHEMBL23901093 | 0.77 | GABRA1 (0.39) | MAOAGABRA1GABRB2PNMTSLC6A4 | |
| SCHEMBL638290 | 0.75 | ALDH1A1 (0.61) | MAOAMAOBARNPC1POLB | |
| SCHEMBL11503378 | 0.75 | SLC6A4 (0.56) | MAOAGABRA1GABRB2PNMTPOLB | |
| SCHEMBL8539519 | 0.74 | GABRA1 (0.50) | MAOAGABRA1GABRB2PNMTSLC6A4 | |
| SCHEMBL28023565 | 0.74 | ALDH1A1 (0.58) | MAOAMAOBARNPC1POLB | |
| SCHEMBL17449716 | 0.72 | HTR2A (0.44) | GABRA1GABRB2PNMTSLC6A4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | CYP11B2, CYP11B1, HMGCR | MAOA 580/4885MAOB 453/4885AR 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.